Biopsy-Validated Deep Learning Mapping of Glioma Infiltration Beyond Contrast Enhancement Using Multiparametric MRI
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Glioblastoma (GBM) exhibits diffuse tumor infiltration beyond contrast-enhancing margins into FLAIR-hyperintense brain tissue, where infiltrative tumor is not visible on conventional MRI. We developed and validated the infiltrative Tumor Burden (iTB) map, a deep learning biomarker that uses multiparametric MRI (mpMRI) to identify infiltrative tumor within these non-enhancing regions.
Methods
Preoperative mpMRI datasets from 80 patients with WHO grade II–IV gliomas and 24 patients with brain metastases were retrospectively analyzed. Imaging included pre- and post-contrast T1-weighted, T2-weighted, FLAIR, dynamic susceptibility contrast perfusion and diffusion MRI-derived maps (rCBV, rCBF, ADC). Spatially localized stereotactic biopsies from non-enhancing glioma regions provided histopathologic ground truth while peritumoral brain metastasis regions served as biologically grounded non-tumor controls. A 3D convolutional neural network was trained on voxel-centered mpMRI patches using patient-level cross-validation and an independent test set, with data augmentation optimized using a greedy local search strategy.
Results
Model development included 121 biopsy-localized samples from 56 glioma patients and 104 non-tumor samples from 26 brain metastasis patients. Augmentation optimization significantly improved independent test-set performance, increasing accuracy from 74.5% to 85.5% and AUC from 0.859 to 0.942 (p = 0.008). Ensemble-derived voxel-wise iTB maps demonstrated low infiltration probabilities in brain metastases and extensive regions of elevated infiltration probability in glioblastoma, consistent with expected biology.
Conclusions
The iTB biomarker generates voxel-wise maps of tumor infiltration within non-enhancing FLAIR abnormalities. Validated against image-localized histopathology and independent testing, it achieved high diagnostic performance and may improve surgical planning, radiotherapy targeting, and assessment of glioma burden.
